MOTIF BIO PLC/S (NASDAQ:MTFB) Shares Down 6.3%

Share on StockTwits

MOTIF BIO PLC/S (NASDAQ:MTFB)’s share price was down 6.3% on Friday . The stock traded as low as $0.13 and last traded at $0.15, approximately 584,317 shares traded hands during trading. An increase of 59% from the average daily volume of 366,707 shares. The stock had previously closed at $0.16.

Several research analysts have recently weighed in on MTFB shares. Northland Securities set a $5.00 price objective on shares of MOTIF BIO PLC/S and gave the stock a “buy” rating in a research note on Monday, July 15th. Zacks Investment Research upgraded shares of MOTIF BIO PLC/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 8th. Finally, ValuEngine upgraded shares of MOTIF BIO PLC/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

The firm’s 50 day moving average price is $0.29 and its two-hundred day moving average price is $0.89. The company has a market capitalization of $2.67 million, a price-to-earnings ratio of -2.14 and a beta of -0.12.

An institutional investor recently raised its position in MOTIF BIO PLC/S stock. Susquehanna International Group LLP lifted its position in shares of MOTIF BIO PLC/S (NASDAQ:MTFB) by 207.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,657 shares of the company’s stock after acquiring an additional 26,740 shares during the period. Susquehanna International Group LLP owned approximately 0.27% of MOTIF BIO PLC/S worth $26,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 9.58% of the company’s stock.

MOTIF BIO PLC/S Company Profile (NASDAQ:MTFB)

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

Featured Story: How is the Producer Price Index calculated?

Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.